Literature DB >> 17470753

Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment.

S W Scheff1, D A Price, F A Schmitt, S T DeKosky, E J Mufson.   

Abstract

OBJECTIVE: To evaluate the total number of synapses in the stratum radiatum (str rad) of the human hippocampal CA1 subfield in individuals with mild Alzheimer disease (mAD), mild cognitive impairment (MCI), or no cognitive impairment (NCI) and determine if synapse loss is an early event in the progression of the disease.
METHODS: Short postmortem autopsy tissue was obtained, and an unbiased stereologic sampling scheme coupled with transmission electron microscopy was used to directly visualize synaptic contacts.
RESULTS: Individuals with mAD had fewer synapses (55%) than the other two diagnostic groups. Individuals with MCI had a mean synaptic value that was 18% lower than the NCI group mean. The total number of synapses showed a correlation with several cognitive tests including those involving both immediate and delayed recall. Total synaptic numbers showed no relationship to the subject's Braak stage or to APOE genotype. The volume of the str rad was reduced in mAD vs the other two diagnostic groups that were not different from each other.
CONCLUSION: These results strongly support the concept that synapse loss is a structural correlate involved very early in cognitive decline in mild Alzheimer disease (mAD) and supports mild cognitive impairment as a transitional stage between mAD and no cognitive impairment.

Entities:  

Mesh:

Year:  2007        PMID: 17470753     DOI: 10.1212/01.wnl.0000260698.46517.8f

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  304 in total

1.  Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss.

Authors:  Santiago V Salazar; Timothy O Cox; Suho Lee; A Harrison Brody; Annabel S Chyung; Laura T Haas; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2018-12-05       Impact factor: 6.167

Review 2.  Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease.

Authors:  Peter Penzes; Jon-Eric Vanleeuwen
Journal:  Brain Res Rev       Date:  2011-01-26

Review 3.  Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications.

Authors:  Kenneth Hensley; Kalina Venkova; Alexandar Christov; William Gunning; Joshua Park
Journal:  Mol Neurobiol       Date:  2011-01-28       Impact factor: 5.590

4.  CSPα knockout causes neurodegeneration by impairing SNAP-25 function.

Authors:  Manu Sharma; Jacqueline Burré; Peter Bronk; Yingsha Zhang; Wei Xu; Thomas C Südhof
Journal:  EMBO J       Date:  2011-12-20       Impact factor: 11.598

Review 5.  Role of APP for dendritic spine formation and stability.

Authors:  Christian K E Jung; Jochen Herms
Journal:  Exp Brain Res       Date:  2011-11-18       Impact factor: 1.972

Review 6.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

7.  Neurodegenerative basis of age-related cognitive decline.

Authors:  R S Wilson; S E Leurgans; P A Boyle; J A Schneider; D A Bennett
Journal:  Neurology       Date:  2010-09-15       Impact factor: 9.910

Review 8.  Ras and Rap signaling in synaptic plasticity and mental disorders.

Authors:  Ruth L Stornetta; J Julius Zhu
Journal:  Neuroscientist       Date:  2010-04-29       Impact factor: 7.519

9.  Factors associated with resistance to dementia despite high Alzheimer disease pathology.

Authors:  D Erten-Lyons; R L Woltjer; H Dodge; R Nixon; R Vorobik; J F Calvert; M Leahy; T Montine; J Kaye
Journal:  Neurology       Date:  2009-01-27       Impact factor: 9.910

10.  Leptin signaling and Alzheimer's disease.

Authors:  Gurdeep Marwarha; Othman Ghribi
Journal:  Am J Neurodegener Dis       Date:  2012-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.